Még nem toboroz
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Még nem toboroz
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
NCT07890376· 2. fázis· Eli Lilly and Company· Forrás
Contact: Eduardo Luna (principal investigator)
Toboroz
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162· 4. fázis· RECORDATI GROUP· Forrás
Contact: Anna Rubio Rodriguez
Toboroz
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608· 2. fázis· Eli Lilly and Company· Forrás
Contact: Eduardo Luna (principal investigator)
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· 3. fázis· Eli Lilly and Company· Forrás
Contact: Eduardo Luna (principal investigator)
Toboroz
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931· 3. fázis· Eli Lilly and Company· Forrás
Contact: Eduardo Luna (principal investigator)
Toboroz
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Fut, nem toboroz
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: Eduardo Luna (principal investigator)
Fut, nem toboroz
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475· 2. fázis· Eli Lilly and Company· Forrás
Contact: Eduardo Luna (principal investigator)
Toboroz
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956· 2. fázis· Eli Lilly and Company· Forrás
Contact: Eduardo Luna (principal investigator)
Fut, nem toboroz
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
NCT03708900· 2. fázis· RECORDATI GROUP· Forrás
Contact: Eduardo Dusty Luna, Dr